Sinocare Inc.'s (SZSE:300298) Most Bullish Insider Is CEO Shao Bo Li, and Their Holdings Value Went up by 4.1% Last Week
Sinocare Inc.'s (SZSE:300298) Most Bullish Insider Is CEO Shao Bo Li, and Their Holdings Value Went up by 4.1% Last Week
Key Insights
關鍵洞察
- Sinocare's significant insider ownership suggests inherent interests in company's expansion
- A total of 3 investors have a majority stake in the company with 58% ownership
- Institutions own 30% of Sinocare
- 三諾生物的顯著內部持股表明了對公司擴張的內在利益
- 共有3名投資者在公司中擁有58%的控股權
- 機構持有Sinocare 30%的股份。
If you want to know who really controls Sinocare Inc. (SZSE:300298), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are individual insiders with 50% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
如果你想知道誰真正控制三諾生物(SZSE:300298),那麼你就需要查看其股份登記的構成。而擁有最大股份的群體是內部人士,擁有50%的股份。也就是說,如果股票上漲,這個群體將獲得最大的收益(或者在市場下滑時損失最多)。
Clearly, insiders benefitted the most after the company's market cap rose by CN¥593m last week.
顯然,上個月公司市值增長了59300萬人民幣,內部人士獲益最大。
In the chart below, we zoom in on the different ownership groups of Sinocare.
在下圖中,我們放大了三諾生物的不同股權結構。
What Does The Institutional Ownership Tell Us About Sinocare?
機構持有情況對三諾生物意味着什麼?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
許多機構的表現與近似當地市場的指數進行比較。因此,他們通常更加關注那些被納入主要指數的公司。
As you can see, institutional investors have a fair amount of stake in Sinocare. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Sinocare's historic earnings and revenue below, but keep in mind there's always more to the story.
如您所見,機構投資者在三諾生物中擁有相當比例的股份。這表明在專業投資者中有一定的可信度。但我們不能僅僅依賴這一事實,因爲機構有時也會做出錯誤的投資,就像任何人一樣。當多個機構共同持有一隻股票時,總是存在它們處於「擁擠交易」的風險。當這種交易出現問題時,多個參與方可能會爭相快速賣出股票。在沒有成長曆史的公司中,這種風險更高。您可以在下面看到三諾生物的歷史盈利和營業收入,但請記住,總是有更多故事。
We note that hedge funds don't have a meaningful investment in Sinocare. With a 26% stake, CEO Shao Bo Li is the largest shareholder. Meanwhile, the second and third largest shareholders, hold 22% and 9.4%, of the shares outstanding, respectively.
我們注意到對三諾生物的對沖基金沒有重大投資。首席執行官肖博利持有26%的股份,是最大的股東。同時,第二和第三大股東分別持有22%和9.4%的在外流通股。
To make our study more interesting, we found that the top 3 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.
爲了讓我們的研究更有趣,我們發現前三大股東在公司中擁有多數股權,意味着他們有足夠的權力影響公司的決策。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
雖然研究一家公司機構的所有權數據是有意義的,但研究分析師的看法也同樣重要,以了解市場的動態。很多分析師關注這隻股票,因此查看他們的預測也可能是值得的。
Insider Ownership Of Sinocare
三諾生物的內部持股情況
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
雖然內部人的精確定義可能是主觀的,但幾乎所有人都認爲董事會成員都是內部人。管理層最終要向董事會負責。然而,管理者成爲執行董事會成員並不罕見,尤其是在他們是創始人或首席執行官的情況下。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常認爲內部人擁有股份是一件好事。然而,在某些情況下,這使得其他股東更難讓董事會對決策負責。
Our information suggests that insiders maintain a significant holding in Sinocare Inc.. Insiders own CN¥7.5b worth of shares in the CN¥15b company. That's quite meaningful. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.
我們的信息顯示,三諾生物的內部人士持有相當可觀的股份。內部人士在這間市值150億的公司中擁有價值75億人民幣的股份。這是相當有意義的。大多數人會說,這顯示出與股東之間有較好的一致性,尤其是在這樣規模的公司中。您可以點擊這裏查看這些內部人士是否在買入或賣出。
General Public Ownership
公衆持股
With a 19% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Sinocare. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
公衆一般擁有19%的股份,主要由個人投資者組成,對三諾生物有一定的影響力。雖然這一群體並不一定能做決定,但無疑可以對公司的運行產生實際影響。
Next Steps:
下一步:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 3 warning signs we've spotted with Sinocare .
我發現了解一個公司到底是誰擁有的非常有趣。但要真正獲得洞見,我們還需要考慮其他信息。爲此,您應該知道我們發現的三大警告信號與三諾生物有關。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果你像我一樣,你可能想考慮這家公司是會增長還是縮小。幸運的是,你可以查看這份免費的報告,了解分析師對其未來的預測。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的數字是根據過去十二個月的數據計算得出的,指的是截至財務報表日期的月份最後一天的12個月期間。這可能與完整年度的年報數字不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。